博瑞医药预告2025业绩大降 东方金诚发关注公告

Group 1 - The core viewpoint of the news is that Borui Pharmaceutical is expected to experience a significant decline in net profit for the year 2025, with projections indicating a decrease of 67.28% to 78.17% compared to the previous year [1] - The forecasted net profit attributable to the parent company for 2025 is estimated to be between 41.3 million yuan and 61.9 million yuan, while the net profit after deducting non-recurring gains and losses is expected to range from 430,000 yuan to 2.49 million yuan, reflecting a year-on-year decrease of 86.21% to 97.62% [1] - The decline in performance is attributed to several factors, including changes in flu trends, shifts in competitive landscape, fluctuations in customer demand, reduced operating revenue and gross profit, increased depreciation from completed construction projects, and higher R&D expenses due to increased investment in innovative drugs [1] Group 2 - Dongfang Jincheng International Credit Rating Co., Ltd. has maintained the credit rating of Borui Pharmaceutical and its convertible bonds at AA- with a stable outlook, following a regular tracking rating on May 27, 2025 [2] - The rating results are effective from the date of the report and will remain valid throughout the duration of the rated debt [2] - Dongfang Jincheng will continue to monitor the developments related to Borui Pharmaceutical's operational and financial status and disclose any impacts on the credit rating and outlook for both the company and its convertible bonds [2]